Johnson & Johnson $JNJ Holdings Lifted by Dominguez Wealth Management Solutions Inc.

Dominguez Wealth Management Solutions Inc. grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.8% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 24,025 shares of the company’s stock after acquiring an additional 183 shares during the quarter. Johnson & Johnson accounts for approximately 2.5% of Dominguez Wealth Management Solutions Inc.’s holdings, making the stock its 8th biggest holding. Dominguez Wealth Management Solutions Inc.’s holdings in Johnson & Johnson were worth $3,670,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the business. Thurston Springer Miller Herd & Titak Inc. increased its stake in shares of Johnson & Johnson by 23.2% in the second quarter. Thurston Springer Miller Herd & Titak Inc. now owns 28,009 shares of the company’s stock worth $4,279,000 after buying an additional 5,277 shares during the period. Centurion Wealth Management LLC increased its stake in shares of Johnson & Johnson by 8.1% in the second quarter. Centurion Wealth Management LLC now owns 5,526 shares of the company’s stock worth $844,000 after buying an additional 416 shares during the period. Douglas Lane & Associates LLC increased its stake in shares of Johnson & Johnson by 2.4% in the second quarter. Douglas Lane & Associates LLC now owns 632,425 shares of the company’s stock worth $96,603,000 after buying an additional 14,750 shares during the period. TruWealth Advisors LLC increased its stake in shares of Johnson & Johnson by 1.5% in the second quarter. TruWealth Advisors LLC now owns 5,100 shares of the company’s stock worth $779,000 after buying an additional 77 shares during the period. Finally, RDA Financial Network increased its stake in shares of Johnson & Johnson by 2.5% in the second quarter. RDA Financial Network now owns 6,059 shares of the company’s stock worth $926,000 after buying an additional 150 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages recently commented on JNJ. Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday. Royal Bank Of Canada lifted their target price on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an “outperform” rating in a research note on Thursday, July 17th. Barclays boosted their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research report on Thursday, July 17th. Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Finally, UBS Group boosted their price objective on shares of Johnson & Johnson from $180.00 to $190.00 and gave the company a “buy” rating in a research report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $176.29.

Johnson & Johnson Stock Down 0.2%

Shares of Johnson & Johnson stock opened at $178.10 on Friday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $181.16. The company has a market cap of $428.93 billion, a P/E ratio of 19.05, a PEG ratio of 2.27 and a beta of 0.40. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The company’s fifty day simple moving average is $170.81 and its two-hundred day simple moving average is $161.29.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company’s revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were given a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. Johnson & Johnson’s dividend payout ratio is currently 55.61%.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.